The Month in Uterine Cancer Research

April 2026 brought a diverse set of research on uterine and endometrial cancer, with the strongest threads running through surgical outcomes, the growing complexity of molecular tumor classification, and early findings on how the immune system, including the bacteria that live in uterine tissue, may shape how cancer behaves. A few papers add important nuance to messages the community hears often: that a POLE mutation means excellent prognosis, and that molecular tests reliably classify tumors. It is worth noting that several of April's most clinically discussed papers, including a comprehensive endometrial cancer review, a Phase II interim analysis of a PD-1/CTLA-4 checkpoint inhibitor, and the GINECO-UTOLA ctDNA trial, appeared in subscription journals and cannot be summarized here.

The papers highlighted here represent a selection of those published during the month. The papers were selected and summarized by AI. Accuracy of the summaries was confirmed by a scientist. This digest incorporates only open-access research articles that are free to be read by the entire community and that are explicitly licensed to be shared and reused.

Surgical choices and a complication people worry about: new lymphedema data

Lymphedema (swelling in the legs or pelvis from damage to the lymphatic system) is one of the most persistent quality-of-life concerns people raise after surgery for endometrial cancer. New data offers some reassurance for one specific surgical approach.

• Researchers followed 113 people with endometrial cancer who underwent vNOTES hysterectomy (a minimally invasive approach performed entirely through the vagina, called vaginal natural orifice transluminal endoscopic surgery) combined with sentinel lymph node (SLN) mapping, a technique in which only the first lymph node or nodes most likely to contain cancer cells are removed and tested, rather than a larger number. The SLN mapping was successful in 102 of the patients, and at 12 months, only 1% of participants met criteria for mild self-reported lymphedema; no clinical lymphedema was detected in the groin area. The finding suggests that when vNOTES is combined with SLN mapping, lymphedema risk appears very low, and patients can ask their surgeon whether this option is appropriate for their situation. This was a retrospective, single-center study; longer follow-up data will strengthen these findings. (Read the full paper)

Understanding your tumor's molecular "type" and why it shapes your treatment

Molecular tumor testing is now a standard part of endometrial cancer care and results directly guide which treatments your team will recommend. Two complementary reviews published this month make the case for why these tests exist and what the results actually mean.

• A review in Frontiers in Oncology maps the five molecular subtypes recognized in current endometrial cancer care: POLE-mutated tumors (a change in a DNA-proofreading gene), MMR-deficient/MSI-H tumors (mismatch repair-deficient/microsatellite instability-high, which are abnormalities in DNA repair), TP53-abnormal tumors (carrying mutations in the p53 tumor-suppressor gene), NSMP ER-positive tumors (no specific molecular profile, driven by estrogen hormone receptors), and NSMP ER-negative tumors (no specific molecular profile). The review explains which targeted therapies are matched to each subtype and how tumors can develop resistance over time. (Read the full paper)
• A paired review in Cancers focuses specifically on what each test measures and how results integrate into the FIGO 2023 staging system (the internationally used framework for staging and risk-stratifying endometrial cancer) both at initial diagnosis and at recurrence. It covers POLE sequencing, MMR protein immunohistochemistry (IHC, a tissue staining technique that shows whether key DNA repair proteins are present), HER2 testing, and estrogen and progesterone receptor testing. This review explains the practical implications of each result and their importance in precise diagnosis and guiding clinical treatment decisions. (Read the full paper)

When the molecular picture doesn't fit neatly: two important nuances

Molecular classification has transformed endometrial cancer care, but two papers this month are honest reminders that the picture is not always straightforward and that knowing the right follow-up question can matter.

• A study used whole-exome and RNA sequencing to analyze 81 high-grade endometrial cancers, including serous carcinoma, clear cell carcinoma, grade 3 endometrioid carcinoma, and carcinosarcoma (a rare, aggressive subtype containing both carcinoma and sarcoma elements). Researchers found significant disagreement among three different methods used to classify tumors; TP53 mutation sequencing, p53 protein immunostaining, and copy number analysis each sometimes produced different answers for the same tumor. Separately, RNA analysis identified three biological patterns cutting across subtype boundaries, with an EMT-like (epithelial-to-mesenchymal transition) pattern, which is common in carcinosarcoma, as being associated with stemness and worse outcomes. The patient-facing message is important: for high-grade tumors, conflicting test results are a real phenomenon reflecting genuine biological complexity, not a laboratory error. This work serves as a foundation to resolve classification challenges in this cancer. (Read the full paper)
• A published case report describes a patient with poorly differentiated endometrial cancer whose tumor showed MMR deficiency (a DNA repair problem) by staining the cells, but was microsatellite stable (MSS) by molecular PCR testing, meaning the DNA-level analysis suggested no such DNA repair problem. The authors identified MLH1 promoter methylation (a chemical silencing of the MLH1 gene, which encodes one of the mismatch repair proteins) as the underlying explanation. Although this is only a single case, this scenario has direct clinical consequences: it affects both immunotherapy eligibility decisions and whether genetic screening for Lynch syndrome is appropriate for that patient. (Read the full paper)

POLE mutations and excellent prognosis with an honest footnote

A POLE mutation (a change in the POLE gene, which proofreads DNA during cell division) is widely recognized as a favorable sign in endometrial cancer, associated with very good long-term outcomes in the large majority of cases. A case report published this month, paired with a systematic review of the published literature, adds a nuance worth knowing about.

• A patient with all the hallmarks of a POLE-mutated endometrioid endometrial cancer, a subtype typically considered low-risk, developed metastases 16 years after initial surgery. The authors' systematic review confirmed that severe late recurrences in POLE-mutated tumors are extremely rare, and none of the common molecular markers tested explained the recurrence. A POLE mutation remains a strong favorable sign, and the vast majority of POLE-mutated tumors behave accordingly. This study highlights the need for ongoing research to improve molecular tools and refine surveillance to be able to identify which small minority of POLE-mutated endometrial tumors may behave more aggressively. (Read the full paper)

Immune cells inside the tumor predict outcomes, and AI can now count them

Tumor-infiltrating lymphocytes (TILs, immune cells that move into and through a tumor) have been studied as a signal of how the immune system is engaging with cancer. A new study using artificial intelligence to measure them consistently across a large cohort finds they matter independently of other known factors.

• Using AI to quantify TILs in digitized tissue slides from 659 people with endometrial cancer, researchers found that patients with high TIL counts had significantly better progression-free survival (the length of time without the cancer growing or spreading; hazard ratio 0.61) and overall survival (hazard ratio 0.54) compared to those with low TIL counts, even after accounting for other variables. TIL status held up as an independent prognostic factor on multivariate analysis, and MMR deficiency was more common in high-TIL tumors, a connection that may help explain why MMR-deficient tumors tend to respond well to immunotherapy. AI-assisted TIL quantification is not yet standard clinical practice, but this well-powered study suggests it may one day become a routine part of pathology reporting. (Read the full paper)

The uterine microbiome may influence how your immune system fights cancer

Interest in how bacteria that live in and around the body interact with cancer is growing rapidly. A new study from a high-impact journal identifies a specific bacterium in uterine tissue that appears to activate the immune system's defenses against endometrial cancer.

• Researchers analyzed tumor samples and multi-omics data (combining genomic, metabolomic, and microbial profiling) from 60 people with endometrial cancer and 18 with benign uterine conditions. They identified Bacillus megaterium KCTC 3007, a bacterium found within uterine tissue, as associated with longer recurrence-free survival. The proposed mechanism: this bacterium produces a compound called trimethylamine N-oxide (TMAO), which in laboratory experiments boosted the activity of CD8+ T cells (the immune system's cancer-killing cells) through type I interferon signaling pathways. Treating cells with TMAO alone replicated the immune-activating effect. This is still preclinical research and no probiotic supplement or TMAO therapy is currently being tested in endometrial cancer clinical trials, but it builds a mechanistic case for the uterine microbiome as a potential future therapeutic target and is a meaningful step in understanding the biology. (Read the full paper)

Endometriosis and endometrial cancer: shared biology and what it means

Many people with a history of endometriosis wonder whether it affects their endometrial cancer risk and how. A review published this month examines what the research actually shows.

• The review covers the biological overlaps between endometrial cancer and endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus. Both are driven by estrogen, involve chronic inflammation, and share mutations in genes including PTEN and ARID1A. Epidemiological data suggests a modest increase in endometrial cancer risk associated with endometriosis, though the absolute risk remains low, and factors like weight, metabolic health, and detection patterns complicate the picture. The review also covers emerging noninvasive biomarkers and the molecular basis for how some endometriosis lesions may, in rare cases, undergo changes toward malignancy. Having endometriosis does not mean you will develop endometrial cancer, but there is shared biology. If you have endometriosis, knowing the primary early warning sign of endometrial cancer (unexpected or abnormal uterine bleeding) and discussing your personal and family history with your gynecologist is a reasonable and informed step. (Read the full paper)

What Does This Mean for Me?

Should I ask my oncologist about molecular tumor testing?

Several papers this month reinforce that molecular testing now directly shapes which treatments your team will recommend for endometrial cancer. If you haven't discussed your tumor's molecular profile, a useful opening question is: "Has my tumor been tested for POLE mutations, MMR deficiency, HER2, and hormone receptors, and what did those results mean for my treatment plan?" If your tumor showed conflicting MMR results, for example, abnormal staining but normal molecular testing, it is worth asking specifically whether MLH1 methylation testing was done, as this can clarify both your immunotherapy options and whether genetic counseling about Lynch syndrome would be appropriate.

I've heard that a POLE mutation means a great prognosis. Is that always true?

A POLE mutation is a strong favorable sign, and the large majority of people with POLE-mutated endometrial cancer do very well. This month's case report of a late recurrence, 16 years after initial treatment, is genuinely rare, not representative of typical POLE outcomes. What it does reinforce is something that applies to all endometrial cancers, regardless of molecular subtype: long-term follow-up matters. Researchers are actively working on better tools to identify the very small minority of POLE-mutated tumors that may need closer monitoring over time.

The research on the microbiome and antitumor immunity sounds exciting. Is there anything I can do with it now?

Not yet in any clinical sense. The Bacillus megaterium finding is early-stage science - interesting and mechanistically promising, but not at the point where it translates into any actionable recommendation. No probiotic, supplement, or TMAO product is currently being tested in endometrial cancer clinical trials. The most meaningful practical step remains staying connected to your care team, asking about clinical trial eligibility at your next visit, and promptly noting any symptoms, particularly unexpected bleeding. The microbiome research is worth watching as it moves forward.

OCRA has a wealth of patient education and support programming, including programs specifically for uterine and endometrial cancer patients. Click here to learn more.

Uterine and endometrial cancer patients are also eligible to participate in our Living Lab cancer registry. Learn more here.

This digest is prepared by OCRA (Ovarian Cancer Research Alliance) for patients, caregivers, and advocates. It is intended to inform, not to guide individual treatment decisions. Please speak with your care team about what research findings may mean for your specific situation.

Sources

Directly Referenced in This Digest

• Kurtulus D, et al. "Lymphedema After vNOTES-Assisted Endometrial Cancer Surgery With Sentinel Lymph Node Biopsy." Current Oncology. April 2026. PMID 42041727. https://doi.org/10.3390/curroncol33040208
• Waseem S, et al. "Precision Oncology in Gynecologic Cancers: Molecular Taxonomy and Targeted Therapeutics." Frontiers in Oncology. April 2026. PMID 42022325. https://doi.org/10.3389/fonc.2026.1785469
• Desouki MM, Mager KL. "Biomarkers with Therapeutic and Prognostic Applications in Gynecologic Malignancies." Cancers. April 2026. PMID 42073573. https://doi.org/10.3390/cancers18081248
• Kawazu M, et al. "Genomic and Transcriptomic Analysis of High-Grade Endometrial Carcinoma: Heterogeneity and Classification Challenges." Cancer Research Communications. April 2026. PMID 41911343. https://doi.org/10.1158/2767-9764.CRC-25-0589
• Qu Z, et al. "MLH1 Promoter Methylation as the Cause of Discordant MMR/MSI Status in Endometrial Cancer: A Case Report." Discover Oncology. April 2026. PMID 42001360. https://doi.org/10.1007/s12672-026-05050-9
• Donati E, et al. "Rare Late Neuromeningeal Relapse of POLE-Mutated Endometrial Carcinoma: Case Report and Systematic Review." Current Oncology. April 2026. PMID 42041738. https://doi.org/10.3390/curroncol33040219
• Hada T, et al. "AI-Assessed Tumor-Infiltrating Lymphocytes as an Independent Prognostic Marker in Endometrial Cancer." Cancer Reports. April 2026. PMID 41958112. https://doi.org/10.1002/cnr2.70535
• Min K, et al. "Bacillus megaterium and TMAO Promote Antitumor Immunity in Endometrial Cancer via CD8+ T Cell Activation." Microbiome. April 2026. PMID 42010642. https://doi.org/10.1186/s40168-026-02373-1
• Marczuk KM, et al. "Endometriosis and Endometrial Cancer: Biological Links and Clinical Implications." Journal of Clinical Medicine. April 2026. PMID 42074694. https://doi.org/10.3390/jcm15082891

Additional Open-Access Papers Published in April 2026 on Related Topics

• Radulovich N, et al. Cancer Research Communications. April 2026. PMID 41886729. https://doi.org/10.1158/2767-9764.CRC-25-XXXX (Preclinical: cediranib + BKM120 dual VEGF/PI3K targeting in patient-derived organoid and xenograft models of rare mixed endometrial carcinoma; in vivo synergy demonstrated.)
• Takahashi K, et al. Journal of Applied Clinical Medical Physics. April 2026. PMID 41957932. https://doi.org/10.1002/acm2.XXXXX (Deep learning auto-contouring model for organs at risk in image-guided brachytherapy for endometrial and cervical cancer; 30-second processing time per case.)
• Bebelman S, et al. Cancer Reports. April 2026. PMID 41980904. https://doi.org/10.1002/cnr2.XXXXX (Methodological comparison of short-read vs. long-read 16S rRNA microbiome sequencing strategies for uterine microbiome profiling in endometrial cancer; highlights underrepresentation of Māori and Pacific women in the literature.)
• Hao C, et al. Cancer Medicine. April 2026. PMID 41987392. https://doi.org/10.1002/cam4.XXXXX (Preclinical: ANKRD62 promotes endometrial cancer cell proliferation and migration via NF-κB signaling; proposed as a potential therapeutic target.)
• Chen Y, et al. BMC Genomic Data. April 2026. PMID 42062899. https://doi.org/10.1186/s12863-026-XXXXX (Proteomics/bioinformatics: IMPDH1 overexpression in endometrial cancer associated with worse prognosis and reduced immune cell infiltration; proposed as an immune evasion-related biomarker.)
• Wang L, et al. Journal of Biomedical Optics. April 2026. PMID 42063581. https://doi.org/10.1117/1.JBO.XXXXX (Preclinical technology: optical-resolution photoacoustic microscopy for vascular characterization in endometrial cancer; AUC 0.943 for distinguishing normal/benign from EC/EIN tissue.)
• Zhang XX, et al. Nutrients. April 2026. PMID 42075034. https://doi.org/10.3390/nuXXXXXXXX (Preclinical: Saikosaponin D, a compound derived from traditional herbal medicine, induces cell cycle arrest, autophagy, and endoplasmic reticulum stress in endometrial cancer cells and reduces xenograft tumor growth in mice.)

Papers Excluded Due to Licensing Restrictions

The following papers address topics relevant to the community and may be openly available but have licensing terms that are unclear or do not permit inclusion in this digest.

• Sarsam H, et al. British Journal of Radiology. April 2026. PMID 40704674. https://doi.org/10.1093/bjr/tqaf176 (Radiological review of rare and uncommon female pelvic tumors, including uterine sarcomas and leiomyosarcoma.)
• Benguerfi S, et al. Clinical Cancer Research. April 2026. PMID 41537701. https://doi.org/10.1158/1078-0432.CCR-25-2959 (irculating tumor DNA (ctDNA) as a prognostic and monitoring biomarker in metastatic endometrial cancer treated with olaparib - GINECO-UTOLA phase II trial.)
• [Author et al.] Cancer Prevention Research. April 2026. PMID 41560424. https://doi.org/10.1158/1940-6207.CAPR-25-0176 (Mendelian randomization study examining female reproductive traits, including AMH levels and menopause timing, as risk factors for hormone-sensitive cancers including endometrial cancer.)
• [Author et al.] Molecular Cancer Research. April 2026. PMID 41563767. https://doi.org/10.1158/1541-7786.MCR-25-0544 (Preclinical study of MIG-6/HDAC1 regulation of angiogenesis and tumor growth in PTEN-deficient endometrioid endometrial cancer.)
• [Author et al.] Cancer Prevention Research. April 2026. PMID 41630399. https://doi.org/10.1158/1940-6207.CAPR-25-0444 (Prospective feasibility study of the progesterone challenge test as a risk stratification tool for endometrial cancer in postmenopausal individuals with abnormal uterine bleeding.)
• [Author et al.] Cancer Epidemiology, Biomarkers & Prevention. April 2026. PMID 41665916. https://doi.org/10.1158/1055-9965.EPI-25-1483 (Methodological study comparing agreement between SEER database and Medicare claims-derived data on uterine cancer treatment.)
• [Author et al.] International Journal of Medical Robotics and Computer Assisted Surgery. April 2026. PMID 41859856. https://doi.org/10.1002/rcs.70148 (Prospective feasibility study of a robotic retroperitoneal approach to para-aortic lymphadenectomy in intermediate- and high-risk endometrial cancer.)
• [Author et al.] Anticancer Research. April 2026. PMID 41895743. https://doi.org/10.21873/anticanres.18099 (mpact of biopsy diagnostic method (blind sampling vs. hysteroscopy-guided) on prognosis of stage I endometrioid cancer.)
• [Author et al.] Psycho-Oncology. April 2026. PMID 41919965. https://doi.org/10.1002/pon.70444 (Qualitative analysis of 24 women's experiences of receiving and using information across their endometrial cancer diagnosis and treatment journey, Australia.)
• [Author et al.] Gynecologic Oncology. April 2026. PMID 41930528. https://doi.org/10.1016/j.ygyno.2026.03.009 (Immunotherapy response rates by anatomical recurrence site - within vs. outside previously irradiated field - in recurrent endometrial and cervical cancer.)
• [Author et al.] Archives of Gynecology and Obstetrics. April 2026. PMID 41931130. https://doi.org/10.1007/s00404-026-08370-x (Comparison of FIGO 2023 staging system with and without molecular classification vs. FIGO 2009 in 172 endometrial cancer patients; stage migration analysis.)
• [Author et al.] Future Oncology. April 2026. PMID 41934341. https://doi.org/10.1080/14796694.2026.2650440 (Clinical risk factors and inflammatory biomarker predictors of 2-year recurrence after standard surgery for endometrial cancer; predictive model development.)
• [Author et al.] Future Oncology. April 2026. PMID 41943281. https://doi.org/10.1080/14796694.2026.2638677 (Plain language patient summary of the DUO-E study examining durvalumab with or without olaparib in advanced endometrial cancer.)
• [Author et al.] Journal of Obstetrics and Gynaecology Research. April 2026. PMID 41947481. https://doi.org/10.1111/jog.70270 (Case report of large cell neuroendocrine carcinoma of the endometrium treated with the DUO-E regimen.)
• [Author et al.] Archives of Gynecology and Obstetrics. April 2026. PMID 41954781. https://doi.org/10.1007/s00404-026-08414-2 (Prospective case series of vNOTES hysterectomy for giant polymyomatous uteri in nulliparous women; feasibility and perioperative outcomes.)
• [Author et al.] Chinese Journal of Pathology. April 2026. PMID 41956747. https://doi.org/10.3760/cma.j.cn112151-20250820-00564 (Validation study of a histopathological scoring system to identify POLE-mutated endometrial cancer without sequencing.)
• [Author et al.] Journal of Obstetrics and Gynaecology Research. April 2026. PMID 41968800. https://doi.org/10.1111/jog.70269 (Case report of stage IVB endometrial carcinoma with respiratory failure treated with weekly paclitaxel-carboplatin under mechanical ventilation.)
• [Author et al.] JAMA. April 2026. PMID 41973450. https://doi.org/10.1001/jama.2026.2248 (Comprehensive clinical review of endometrial cancer covering epidemiology, diagnosis, surgical staging, molecular subtypes, and adjuvant therapy.)
• [Author et al.] African Journal of Reproductive Health. April 2026. PMID 41979239. https://doi.org/10.29063/ajrh2026/v30i7.5 (Case-control study of systemic antioxidant levels and oxidative stress markers in 200 women with endometrial cancer vs. controls.)
• [Author et al.] Gynecological Endocrinology. April 2026. PMID 41999195. https://doi.org/10.1080/09513590.2026.2659439 (Case series of relugolix combination therapy for symptomatic adenomyosis co-existing with uterine fibroids.)
• [Author et al.] Gynecologic Oncology. April 2026. PMID 42000370. https://doi.org/10.1016/j.ygyno.2026.03.014 (Phase II interim analysis of cadonilimab, a PD-1/CTLA-4 bispecific checkpoint inhibitor, plus chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer.)
• [Author et al.] Gynecologic Oncology. April 2026. PMID 42000371. https://doi.org/10.1016/j.ygyno.2026.03.010 (Retrospective cohort study examining whether GLP-1 receptor agonists combined with progestins reduced hysterectomy risk vs. progestins alone in fertility-sparing management of endometrial intraepithelial neoplasia and early endometrial cancer.)
• [Author et al.] Gynecologic Oncology. April 2026. PMID 42000378. https://doi.org/10.1016/j.ygyno.2026.02.009 (Decision tree cost-effectiveness analysis comparing universal next-generation sequencing vs. selective profiling strategies for advanced endometrial cancer management.)
• [Author et al.] Journal of Oncology Pharmacy Practice. April 2026. PMID 42012269. https://doi.org/10.1177/10781552261443700 (Retrospective cohort of immune checkpoint inhibitor-induced hyperthyroidism; endometrial cancer identified as a risk factor among cancer types included.)
• [Author et al.] Health Informatics Journal. April 2026. PMID 42018984. https://doi.org/10.1177/14604582261445744 (Cross-sectional evaluation of quality and reliability of endometrial cancer-related videos on Chinese short-video platforms.)
• [Author et al.] Translational Oncology. April 2026. PMID 42030786. https://doi.org/10.1016/j.tranon.2026.102774 (Preclinical study of MUC16's role in endometrial cancer progression and modulation of sensitivity to lapatinib.)
• [Author et al.] BMJ Case Reports. April 2026. PMID 42031396. https://doi.org/10.1136/bcr-2025-269159 (Case report of uterine angiosarcoma diagnosed by endometrial biopsy, with transient metastasis regression on oral progesterone before disease progression.)
• [Author et al.] International Journal of Gynecological Cancer. April 2026. PMID 42034020. https://doi.org/10.1016/j.ijgc.2026.104675 (NCDB retrospective analysis showing surgical approach was not independently associated with overall survival in clinical stage I uterine leiomyosarcoma.)
• [Author et al.] Frontiers in Bioscience (Landmark Edition). April 2026. PMID 42052842. https://doi.org/10.31083/FBL49257 (Machine learning framework for classification of FIGO stage IA vs. IB endometrial cancer using MRI images.)
• [Author et al.] Materials Today Bio. April 2026. PMID 42058965. https://doi.org/10.1016/j.mtbio.2026.103121 (Review of biomaterial-based multimodal therapeutic platforms for endometrial cancer, including subtype-guided drug delivery and fertility-preserving strategies.)
• [Author et al.] Oncology Research. April 2026. PMID 42065043. https://doi.org/10.32604/or.2026.071213 (Case report of endometrial cancer neuroendocrine carcinoma with MMR deficiency treated with camrelizumab plus chemotherapy; 26 months progression-free.)
• [Author et al.] Oncology Research. April 2026. PMID 42065070. https://doi.org/10.32604/or.2026.068833 (Preclinical study of HPDL regulation of histone lactylation via LDHA/LDHB to promote endometrial cancer cell proliferation.)
• [Author et al.] International Journal of Gynecological Cancer. April 2026. PMID 42068680. https://doi.org/10.1016/j.ijgc.2026.104683 (Review of multidisciplinary management of early-stage uterine sarcoma, covering leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma.)
• [Author et al.] Anti-Cancer Drugs. April 2026. PMID 42068992. https://doi.org/10.1097/CAD.0000000000001824 (Case series of pembrolizumab in undifferentiated/dedifferentiated endometrial cancer; high MMR deficiency rate; 5 partial or complete responses among 11 patients.)
• [Author et al.] International Journal of Gynecological Cancer. April 2026. PMID 42070324. https://doi.org/10.1016/j.ijgc.2026.104698 (Narrative review of androgen receptor signaling in endometrial cancer and potential androgen receptor-targeted therapeutic strategies.)
• [Author et al.] Oncology (Williston Park). April 2026. PMID 42084521. https://doi.org/10.46883/2026.25921071 (Case study and literature review of synchronous endometrial cancer and ovarian cancer in a 47-year-old woman.)